JP7228169B2 - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP7228169B2
JP7228169B2 JP2020553868A JP2020553868A JP7228169B2 JP 7228169 B2 JP7228169 B2 JP 7228169B2 JP 2020553868 A JP2020553868 A JP 2020553868A JP 2020553868 A JP2020553868 A JP 2020553868A JP 7228169 B2 JP7228169 B2 JP 7228169B2
Authority
JP
Japan
Prior art keywords
group
pharmaceutical composition
cancer
atl
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020553868A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020090698A1 (ja
Inventor
孫市 酒向
晋平 杉山
祐樹 倉橋
弘臣 脇田
晋也 木村
達郎 渡邉
博志 嬉野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL UNIVERSITY CORPORATION SAGA UNIVERSITY
Ohara Pharmaceutical Co Ltd
Original Assignee
NATIONAL UNIVERSITY CORPORATION SAGA UNIVERSITY
Ohara Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL UNIVERSITY CORPORATION SAGA UNIVERSITY, Ohara Pharmaceutical Co Ltd filed Critical NATIONAL UNIVERSITY CORPORATION SAGA UNIVERSITY
Publication of JPWO2020090698A1 publication Critical patent/JPWO2020090698A1/ja
Application granted granted Critical
Publication of JP7228169B2 publication Critical patent/JP7228169B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020553868A 2018-10-30 2019-10-28 医薬組成物 Active JP7228169B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018203345 2018-10-30
JP2018203345 2018-10-30
PCT/JP2019/042080 WO2020090698A1 (ja) 2018-10-30 2019-10-28 医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2020090698A1 JPWO2020090698A1 (ja) 2021-09-09
JP7228169B2 true JP7228169B2 (ja) 2023-02-24

Family

ID=70462046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020553868A Active JP7228169B2 (ja) 2018-10-30 2019-10-28 医薬組成物

Country Status (3)

Country Link
JP (1) JP7228169B2 (zh)
CN (1) CN112638422B (zh)
WO (1) WO2020090698A1 (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017183217A1 (ja) 2016-04-21 2017-10-26 大原薬品工業株式会社 ５－アザシチジン類の糖部シリルエーテル誘導体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019160127A1 (ja) * 2018-02-19 2019-08-22 大原薬品工業株式会社 Ｄｎｍｔ阻害剤の用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017183217A1 (ja) 2016-04-21 2017-10-26 大原薬品工業株式会社 ５－アザシチジン類の糖部シリルエーテル誘導体

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Cancer Science，2018年12月，Vol. 109, Issue S2，p. 1172, J-3035，The 77th Annual Meeting of the Japanese Cancer Association September 27th(Thu.)-29th (Sat.), 2018
Current Protein and Peptide Science，2015年，Vol. 16，p. 559-570
FUJIKAWA D. et al.，Polycomb-dependent epigenetic landscape in adult T-cell leukemia.，Blood，2016年，Vol.127, No.14，pages 1790 to 1802，doi:10.1182/blood-2015-08-662593
MOMPARLER R.L. et al.，Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combinatio，Clinical Epigenetics，2014年，Vol.6, No.1, Article No.19，pages 1 to 12，doi:10.1186/1868-7083-6-19
NISHIOKA C. et al.，Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blo，Leukemia Research，2008年，Vol.32, No.2，pages 287 to 296，doi:10.1016/j.leukres.2007.05.026
YAN P. et al.，Human T-cell leukemia virus type I-mediated repression of PDZ-LIM domain-containing protein 2 involv，Neoplasia，2009年，Vol.11, No.10，pages 1036 to 1041，doi:10.1593/neo.09752
国立がん研究センター、東京大学、第一三共新規分子標的薬を共同開発 悪性リンパ腫（成人Ｔ細胞白血病リンパ腫含む）に対する第Ｉ相試験開始，国立がん研究センタープレスリリース，2016年03月22日，https://www.ncc.go.jp/jp/information/pr_release/2016/0322/press_release_20160322.pdf

Also Published As

Publication number Publication date
JPWO2020090698A1 (ja) 2021-09-09
WO2020090698A1 (ja) 2020-05-07
CN112638422B (zh) 2023-03-17
CN112638422A (zh) 2021-04-09

Similar Documents

Publication Publication Date Title
ES2401951T3 (es) Combinaciones de sapacitabina o CNDAC con inhibidores de ADN metiltransferasa tales como decitabina y procaína
ES2882223T3 (es) 17Alfa-valerato de cortexolona para el uso en el tratamiento de tumores
NZ583923A (en) Azacytidine analogues and uses thereof
BRPI0715196A2 (pt) Uso de um composto
AU2013202507B2 (en) Inhibition of drug resistant cancer cells
JP5504179B2 (ja) 毒性を低減するためのメトトレキセートアジュバントおよびその使用法
ES2414617T3 (es) Ácidos grasos de cadena de longitud media, sales y triglicéridos en combinación con gemcitabina para el tratamiento del cáncer pancreático
ES2743691T3 (es) Régimen de dosis para sapacitabina y decitabina en combinación para tratar la leucemia mieloide aguda
JP7228169B2 (ja) 医薬組成物
AU2012316266B2 (en) Combination therapy for chemoresistant cancers
PT2754441E (pt) Composição para a prevenção e tratamento de cancro do pulmão de não pequenas células, contendo derivados de pirazino-triazina
CA3068096C (en) Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
AU2012312308B2 (en) Romidepsin and 5-azacitidine for use in treating lymphoma
EA037667B1 (ru) Лечение рака
RU2471486C2 (ru) Противоопухолевое средство для непрерывного внутривенного введения, содержащее цитидиновое производное
AU2009230499B2 (en) Anti-tumor agent comprising cytidine derivative and carboplatin
CN114588269A (zh) Bcl-2抑制剂和HDAC抑制剂的组合物及其用途
US20220347197A1 (en) Use of dnmt inhibitor
NZ622752B2 (en) Romidepsin and 5 - azacitidine for use in treating lymphoma
TW201021801A (en) A pharmaceutical composition for the treatment of cancers
AU2015218471A1 (en) Inhibition of drug resistant cancer cells

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210108

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20210409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230202

R150 Certificate of patent or registration of utility model

Ref document number: 7228169

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150